Rallybio (RLYB) AI Stock Analysis

• Market Cap: $46.92M
• Dividend Yield: N/A
• Average Volume (3M): 283.42K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.93
• Revenue Growth: 12.71%
• EPS Growth: 79.93%
• Country: US
• Employees: 15
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.11
• Shares Outstanding: 5,289,675
• 10 Day Avg. Volume: 220,035
• 30 Day Avg. Volume: 283,421
• PEG Ratio: 0.04
• Price to Book (P/B): 0.53
• Price to Sales (P/S): 36.02
• P/FCF Ratio: -1.04
• Enterprise Value/Market Cap: 0.34
• Enterprise Value/Revenue: 18.32
• Enterprise Value/Gross Profit: 18.39
• Enterprise Value/Ebitda: -0.48
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): -7.8
• Revenue Forecast (FY): N/A

• Rating: 67 Neutral
• Price Target: $10.00 ▲(12.74% Upside)
• Action: Reiterated Date: 03/17/26
• Date: Action: Reiterated 03/17/26

The score is driven by strong technical momentum and a highly positive corporate catalyst (merger plus large financing). These are partially offset by weak underlying financial performance, including ongoing losses and significant cash burn despite low leverage.

Positive Factors

Pro-forma cash runway from merger financing

The announced all‑stock merger with Candid plus an oversubscribed private financing (> $505M) creates an expected pro‑forma cash balance near $700M and runway through 2030. That durable funding materially de‑risks near‑term development financing and enables multiple clinical milestones to be funded without immediate dilution.

Focused rare‑disease and TCE therapeutic pipeline

Rallybio’s strategic focus on rare and severe maternal‑fetal and immune disorders concentrates R&D on high unmet‑need areas where clinical success yields durable commercial exclusivity, premium pricing and regulatory incentives. This targetable, specialized pipeline supports a long‑term value creation pathway if clinical readouts succeed.

Very low leverage / minimal debt burden

A near‑zero debt position gives the company structural financial flexibility to fund R&D and absorb clinical setbacks without interest burden stress. Low leverage preserves optionality for long‑duration biotech programs and complements the new equity financing, reducing refinancing risk as programs advance.

Negative Factors

Persistent negative operating cash flow

Operating cash flow remains substantially negative, reflecting ongoing cash burn to support clinical programs. Even with improved cash burn versus prior years, continued negative FCF necessitates external financing to sustain operations absent near‑term commercialization, making the business structurally financing‑dependent.

Small revenue base and continued unprofitability

Revenue is immaterial and margins are deeply negative, indicating the company is not yet on a path to self‑sustaining operations. Structural reliance on clinical progress rather than product sales means a long runway is required to reach scalable revenues, increasing binary risk tied to trial outcomes.

Severe dilution and loss of existing shareholder stake

Under the merger terms Rallybio holders would retain only ~3.65% of the combined company, a structural dilution that markedly reduces existing shareholders' claim on future upside. Coupled with contingent value rights on legacy assets, this materially changes Rallybio's standalone equity economics and long‑term investor returns.

Rallybio Business Overview & Revenue Model

Company Description

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

How the Company Makes Money

null

Rallybio Financial Statement Overview

Summary

Financials remain weak overall: revenue is still very small and the business is unprofitable with large operating losses and materially negative operating/free cash flow (continued cash burn). The balance sheet is a relative strength due to minimal debt, but shrinking assets/equity reflect ongoing capital consumption.

Income Statement

Revenue remains very small but improved in 2025 (up 27.3% to $0.86M vs. $0.64M in 2024). Profitability is the key weakness: the company continues to run large operating losses (EBIT of -$33.1M in 2025) and remains unprofitable (net loss of -$9.0M in 2025). While losses narrowed sharply versus 2024 (net loss of -$57.8M), margins are still deeply negative and the business is not yet demonstrating a scalable earnings profile.

Balance Sheet

Balance sheet leverage is very low, with minimal debt ($0.18M in 2025) and a near-zero debt burden relative to equity (debt-to-equity ~0.003). The offset is declining asset and equity levels over time (assets down to $62.3M in 2025 from $180.4M in 2022; equity down to $58.0M from $169.3M), consistent with sustained losses and cash burn. Returns to shareholders are negative (return on equity -15.5% in 2025), highlighting continued capital consumption despite the conservative capital structure.

Cash Flow

Cash generation is a major weakness: operating cash flow and free cash flow are materially negative, with 2025 operating cash flow at -$29.8M (improved from -$49.3M in 2024, but still a significant burn). Free cash flow also declined year over year in 2025 (down 14.81%), indicating funding needs likely persist. Cash burn has moderated versus prior years, but the company is still far from self-funding operations.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	858.00K	636.00K	0.00	0.00	0.00
Gross Profit	766.00K	636.00K	-150.00K	-167.00K	-109.00K
EBITDA	-27.97M	-60.37M	-78.78M	-67.72M	-45.39M
Net Income	-8.98M	-57.77M	-74.56M	-66.65M	-47.01M
Balance Sheet
Total Assets	62.26M	68.11M	115.62M	180.44M	182.19M
Cash, Cash Equivalents and Short-Term Investments	54.74M	65.51M	109.93M	168.99M	175.33M
Total Debt	176.00K	154.00K	392.00K	555.00K	0.00
Total Liabilities	4.30M	6.45M	9.44M	11.12M	6.58M
Stockholders Equity	57.96M	61.65M	106.18M	169.32M	175.60M
Cash Flow
Free Cash Flow	-29.81M	-49.28M	-60.28M	-57.34M	-45.87M
Operating Cash Flow	-29.81M	-49.28M	-60.27M	-57.28M	-45.53M
Investing Cash Flow	47.27M	33.49M	27.66M	-112.17M	-2.33M
Financing Cash Flow	16.00K	5.20M	143.00K	51.08M	82.97M

Rallybio Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.87
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RLYB, the sentiment is Positive. The current price of 8.87 is below the 20-day moving average (MA) of 9.08, above the 50-day MA of 6.69, and above the 200-day MA of 5.03, indicating a neutral trend. The MACD of 0.85 indicates Positive momentum. The RSI at 55.88 is Neutral, neither overbought nor oversold. The STOCH value of 10.16 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RLYB.

Rallybio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RLYB	67 Neutral	$46.92M	-3.44	-21.17%	―	12.71%	79.93%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CTXR	50 Neutral	$17.24M	-0.51	-54.40%	―	―	18.73%
MBRX	45 Neutral	$10.99M	-1.17	―	―	―	79.31%
PCSA	45 Neutral	$6.17M	-0.28	-257.81%	―	―	72.88%
APVO	43 Neutral	$4.55M	-0.19	-389.34%	―	―	99.02%
ALLR	40 Underperform	$17.37M	-2.07	-112.05%	―	―	99.82%

Rallybio Corporate Events

Rallybio to Merge with Candid Therapeutics in All-Stock Deal

Rallybio Corporation and Candid Therapeutics announced on March 2, 2026 that Rallybio will acquire Candid in an all-stock merger, after which the combined business will operate as Candid Therapeutics and list on Nasdaq under the ticker CDRX. The deal, unanimously approved by both boards and expected to close in mid-2026 pending regulatory and shareholder approvals, will leave existing Rallybio holders with about 3.65% of the enlarged group and contingent value rights tied to monetization of Rallybio’s legacy assets, while Candid shareholders and new investors will control the balance.

Concurrently, Candid secured an oversubscribed private financing of more than $505 million from a syndicate of prominent healthcare investors, giving the merged company an anticipated cash position of roughly $700 million at closing and runway through 2030. The capital is earmarked to advance Candid’s broad T-cell engager pipeline, including planned 2026 Phase 2 trials of lead asset cizutamig in myasthenia gravis and interstitial lung disease, and positions the renamed company as a well-funded contender in autoimmune drug development under the leadership of current Candid CEO Ken Song.

The most recent analyst rating on (RLYB) stock is a Hold with a $0.62 price target. To see the full list of analyst forecasts on Rallybio stock, see the RLYB Stock Forecast page.

Rallybio Shareholders Approve Reverse Stock Split Amendment

On January 26, 2026, Rallybio Corporation’s stockholders approved an amendment to its Certificate of Incorporation authorizing a reverse stock split of its common stock at a ratio selected by the board, and the company subsequently fixed the split at 1-for-8. The reverse stock split, scheduled to take effect at 12:01 a.m. Eastern Time on February 6, 2026, will consolidate Rallybio’s issued and outstanding shares and result in its common stock trading on a post-split basis under a new CUSIP, a move that typically aims to boost the per-share trading price and can influence the company’s market perception and compliance with stock exchange listing requirements; the vote passed with a strong majority, with more than 34.5 million shares in favor out of approximately 35 million shares voted, indicating broad shareholder support for the capital structure change.

The most recent analyst rating on (RLYB) stock is a Hold with a $0.65 price target. To see the full list of analyst forecasts on Rallybio stock, see the RLYB Stock Forecast page.